Literature DB >> 28523159

Nomograms for predicting recurrence and survival of invasive pathological stage IA non-small cell lung cancer treated by video assisted thoracoscopic surgery lobectomy.

Haiqing Chen1, Xizhao Sui1, Fan Yang1, Jun Liu1, Jun Wang1.   

Abstract

BACKGROUND: A considerable portion of pathological stage (p-stage) IA non-small cell lung cancer (NSCLC) patients suffered from death and recurrence after video assisted thoracoscopic surgery (VATS) lobectomy. The purpose of our study was to develop nomograms to predict which subgroup patients were more likely to suffer from recurrence or death.
METHODS: Data of invasive p-stage IA NSCLC patients who underwent VATS lobectomy at Peking University People's Hospital from September 2006 to April 2014 were analyzed. Multivariate Cox proportional hazards regression was used to develop nomograms. The performance of the nomograms was evaluated by Harrell's concordance index (C-index), calibration plots and risk group stratification.
RESULTS: A total of 422 patients with NSCLC of invasive p-stage IA were included in the study. The median follow-up time was 40 months. Age [hazards ratio (HR) =1.067, 95% confidential interval (CI): 1.006-1.131], lymphovascular invasion (LVI) (HR=4.062, 95% CI: 1.278-12.912) and differentiation (HR =5.747, 95% CI: 2.151-15.353) were independent prognostic factors to predict overall survival (OS). Tumor diameter (HR =3.299, 95% CI: 1.814-6.001), LVI (HR =3.260, 95% CI: 1.221-8.708) and differentiation (HR =3.607, 95% CI: 1.776-7.327) were independent predictors of recurrence free survival (RFS). The nomogram for predicting OS demonstrated stronger discriminatory power than the 7th and 8th T stage systems (C-index: 0.894 for the nomogram, 0.700 for the 7th T stage and 0.742 for the 8th T stage). Likewise, the C-index of the nomogram for predicting RFS was higher than that of the 7th and 8th T stage systems (0.838 for the nomogram, 0.670 for the 7th T stage and 0.723 for the 8th T stage).
CONCLUSIONS: We developed nomograms that could predict individual accurate prognosis for invasive p-stage IA NSCLC patients after VATS lobectomy. Risk stratification by the nomograms might guide further adjuvant chemotherapy and follow-up.

Entities:  

Keywords:  Nomogram; non-small cell lung cancer (NSCLC); prognosis; video assisted thoracoscopic surgery (VATS)

Year:  2017        PMID: 28523159      PMCID: PMC5418285          DOI: 10.21037/jtd.2017.03.130

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  25 in total

1.  Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  David S Ettinger; Douglas E Wood; Dara L Aisner; Wallace Akerley; Jessica Bauman; Lucian R Chirieac; Thomas A D'Amico; Malcolm M DeCamp; Thomas J Dilling; Michael Dobelbower; Robert C Doebele; Ramaswamy Govindan; Matthew A Gubens; Mark Hennon; Leora Horn; Ritsuko Komaki; Rudy P Lackner; Michael Lanuti; Ticiana A Leal; Leah J Leisch; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Karen Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; James Stevenson; Scott J Swanson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2017-04       Impact factor: 11.908

Review 2.  Nomograms in oncology: more than meets the eye.

Authors:  Vinod P Balachandran; Mithat Gonen; J Joshua Smith; Ronald P DeMatteo
Journal:  Lancet Oncol       Date:  2015-04       Impact factor: 41.316

3.  Survival after pathological stage IA nonsmall cell lung cancer: tumor size matters.

Authors:  Ozcan Birim; A Pieter Kappetein; Johanna J M Takkenberg; Rob J van Klaveren; Ad J J C Bogers
Journal:  Ann Thorac Surg       Date:  2005-04       Impact factor: 4.330

4.  The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.

Authors:  Ramón Rami-Porta; Vanessa Bolejack; John Crowley; David Ball; Jhingook Kim; Gustavo Lyons; Thomas Rice; Kenji Suzuki; Charles F Thomas; William D Travis; Yi-Long Wu
Journal:  J Thorac Oncol       Date:  2015-07       Impact factor: 15.609

5.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

6.  Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003.

Authors:  S-H Ignatius Ou; Jason A Zell; Argyrios Ziogas; Hoda Anton-Culver
Journal:  Cancer       Date:  2007-10-01       Impact factor: 6.860

7.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

8.  Proposal on incorporating blood vessel invasion into the T classification parts as a practical staging system for stage I non-small cell lung cancer.

Authors:  Yujin Kudo; Hisashi Saji; Yoshihisa Shimada; Jun Matsubayashi; Toshitaka Nagao; Masatoshi Kakihana; Jitsuo Usuda; Naohiro Kajiwara; Tatsuo Ohira; Norihiko Ikeda
Journal:  Lung Cancer       Date:  2013-05-08       Impact factor: 5.705

9.  Upstaging by vessel invasion improves the pathology staging system of non-small cell lung cancer.

Authors:  Tomoshi Tsuchiya; Satoshi Hashizume; Shinji Akamine; Masashi Muraoka; Sumihisa Honda; Koichi Tsuji; Shougo Urabe; Tomayoshi Hayashi; Naoya Yamasaki; Takeshi Nagayasu
Journal:  Chest       Date:  2007-05-15       Impact factor: 9.410

10.  Heterogeneous prognosis and adjuvant chemotherapy in pathological stage I non-small cell lung cancer patients.

Authors:  Chia-Hsin Liu; Yi-Jen Peng; Hong-Hau Wang; Ying-Chieh Chen; Chen-Liang Tsai; Chih-Feng Chian; Tsai-Wang Huang
Journal:  Thorac Cancer       Date:  2015-02-27       Impact factor: 3.500

View more
  4 in total

1.  Performance of a Nomogram Based on the Integration of Inflammation Markers with Tumor Staging in Prognosis Prediction of Stage III Colorectal Cancer.

Authors:  Lin Wang; Jun Xiao; Min-Zhe Li; Wen-Hao Teng; Jing Jia; Lu Lin; Sheng Liu; Xing-Ming Ye; Wei-Dong Zang; Ying Chen
Journal:  Cancer Manag Res       Date:  2020-08-07       Impact factor: 3.989

2.  Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochemical markers.

Authors:  Jianjiao Ni; Tiantian Guo; Yuan Li; Xi Yang; Yida Li; Liqing Zou; Li Chu; Xiao Chu; Shuyan Li; Luxi Ye; Yawei Zhang; Zhengfei Zhu
Journal:  Transl Lung Cancer Res       Date:  2019-12

3.  Tumor Differentiation and EGFR Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery.

Authors:  Lu Yang; Chong Pang; Fei Xu; Guangjian Yang; Haiyan Xu; Changli Wang; Yan Wang
Journal:  Cancer Manag Res       Date:  2020-12-07       Impact factor: 3.989

4.  Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection.

Authors:  Yu-Jia Shen; Li-Qiang Qian; Zheng-Ping Ding; Qing-Quan Luo; Heng Zhao; Wu-Yan Xia; Yuan-Yuan Fu; Wen Feng; Qin Zhang; Wen Yu; Xu-Wei Cai; Xiao-Long Fu
Journal:  Front Oncol       Date:  2021-09-01       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.